Peer-influenced content. Sources you trust. No registration required. This is HCN.
MDLinx
Rapid weight loss from semaglutide use can lead to breast ptosis, mirroring effects seen after bariatric surgery. Healthcare providers should be prepared to counsel patients on this potential outcome and offer strategies for management.
Endocrinology, Diabetes, Metabolism July 17th 2024
A diet high in soluble fiber, protein, and healthy fats can mimic the effects of GLP-1 agonists like Ozempic, offering a safer alternative for weight management and metabolic health.
All Specialties July 10th 2024
GLP-1 receptor agonists, beyond their role in diabetes and obesity management, are showing promise in reducing alcohol cravings, potentially offering a novel approach to treating alcohol use disorder.
Endocrinology, Diabetes, Metabolism June 4th 2024
Healthline
Patients on GLP-1 medications may experience notable changes in breast morphology, such as decreased volume and increased sagging. Medical experts recommend supportive measures and a stable weight before considering surgical interventions.
Obstetrics & Gynecology May 17th 2024
Medical News Today (MNT)
Ozempic, commonly used off-label for weight management, can cause significant facial side effects, termed “Ozempic face,” marked by increased wrinkling and loss of skin elasticity.
Dermatology May 17th 2024
Recent studies suggest that GLP-1 receptor agonists, while primarily used for weight loss, may also impact mental health and behavior, potentially due to their effects on the brain’s reward systems.
Endocrinology, Diabetes, Metabolism April 30th 2024